This continuing medical education activity is provided by Vindico Medical Education. This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Although the development and inclusion of anti-VEGF therapy revolutionized the treatment of retinal vascular diseases, real-world data indicate that clinical outcomes are suboptimal compared with those observed in clinical trials. This is largely due to the high treatment burden of the injection frequency required for the current anti-VEGF therapies. Thus, novel delivery methods are under investigation to provide continuous dosing over a longer period of time. In this education activity, experts in the field of retinal vascular diseases will review best practices regarding the use of recently approved surgical approaches and the data supporting their use in the treatment of neovascular age-related macular degeneration in case-based discussions. They will also explore other novel surgical approaches in late-stage development and their potential role on the current treatment paradigm for retinal vascular diseases.

In this case-based Curbside Consult, Drs. Holekamp and Miller discuss best…

Expiration Date: 7/14/2023

Max Credits: 0.25

In this case-based Curbside Consult, Drs. Holekamp and Miller discuss best…

Expiration Date: 7/14/2023

Max Credits: 0.25

In this case-based Curbside Consult, Drs. Holekamp and Miller discuss best…

Expiration Date: 7/14/2023

Max Credits: 0.25

Educational Tools

• FDA approves faricimab for treatment of wet AMD, DME
• TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration
• Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
• YOSEMITE and RHINE Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale